FBRX vs. ORMP, ASRT, SCYX, CMRX, CNTB, IFRX, HILS, ASMB, ONCY, and IOBT
Should you be buying Forte Biosciences stock or one of its competitors? The main competitors of Forte Biosciences include Oramed Pharmaceuticals (ORMP), Assertio (ASRT), SCYNEXIS (SCYX), Chimerix (CMRX), Connect Biopharma (CNTB), InflaRx (IFRX), Hillstream BioPharma (HILS), Assembly Biosciences (ASMB), Oncolytics Biotech (ONCY), and IO Biotech (IOBT). These companies are all part of the "pharmaceutical preparations" industry.
Forte Biosciences (NASDAQ:FBRX) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk, community ranking and media sentiment.
77.6% of Forte Biosciences shares are owned by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 10.5% of Forte Biosciences shares are owned by insiders. Comparatively, 12.0% of Oramed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Oramed Pharmaceuticals has higher revenue and earnings than Forte Biosciences. Forte Biosciences is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Forte Biosciences presently has a consensus target price of $3.38, indicating a potential upside of 468.37%. Given Forte Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Forte Biosciences is more favorable than Oramed Pharmaceuticals.
Oramed Pharmaceuticals' return on equity of -3.83% beat Forte Biosciences' return on equity.
Forte Biosciences has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals has a beta of 1.87, meaning that its share price is 87% more volatile than the S&P 500.
Oramed Pharmaceuticals received 289 more outperform votes than Forte Biosciences when rated by MarketBeat users. Likewise, 74.64% of users gave Oramed Pharmaceuticals an outperform vote while only 57.78% of users gave Forte Biosciences an outperform vote.
In the previous week, Forte Biosciences had 3 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 9 mentions for Forte Biosciences and 6 mentions for Oramed Pharmaceuticals. Oramed Pharmaceuticals' average media sentiment score of 1.09 beat Forte Biosciences' score of 0.94 indicating that Oramed Pharmaceuticals is being referred to more favorably in the news media.
Summary
Oramed Pharmaceuticals beats Forte Biosciences on 11 of the 16 factors compared between the two stocks.
Get Forte Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for FBRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Forte Biosciences Competitors List
Related Companies and Tools
